SDIX's Q4 Revenues, Loss Decline | GenomeWeb

SDIX's Q4 Revenues, Loss Decline

Feb 25, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SDIX, the firm previously known as Strategic Diagnostics, reported after the close of the market Thursday that its fourth-quarter revenues fell 11 percent, but the firm managed to cut its loss to almost zero for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Related Articles

Feb 11, 2015

Quidel Q4 Revenues Grow 27 Percent on Infectious Disease Sales

Mar 10, 2014

Cellular Dynamics Q4 Revenues up 45 Percent

Aug 12, 2014

Cellular Dynamics' Q2 Revenues Rise 29 Percent

Nov 11, 2014

Cellular Dynamics' Q3 Revenues Rise 41 Percent

Mar 13, 2014

Transgenomic Posts 12 Percent Q4 Revenue Decline

Aug 06, 2014

Instrument, Consumables Sales Drive NanoString's Q2 Revenues up 51 Percent

Breaking News

The Scan

This Week in Nature

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Its Own Version

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

Just the Train Going By

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

New Technique a 'Go'

The House of Lords in the UK approves a bill to allow mitochondrial donation.

Featured White Papers

Reducing the variability of pre-analytical handling of biological samples